Clinical Advances in BTK Inhibitors for Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma: Where Disease-, Treatment-, and Patient-Centric Education Unite
Developed through a strategic collaboration between Medscape Global Oncology and The Leukemia & Lymphoma Society.
New Resources are now available from Medscape Education’s Clinical Advances in BTK Inhibitors for Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma: Where Disease-, Treatment-, and Patient-Centric Education Unite.
Did you know that the treatment landscape for relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) and R/R mantle cell lymphoma (MCL) is rapidly evolving? Join the experts as we delve deeper into this topic.
Clinical Advances in BTK Inhibitors for Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma: Where Disease-, Treatment-, and Patient-Centric Education Unite is a thematic curriculum for physicians, dedicated to improving the management of patients with CLL and MCL. Learn More
Steering Committee
Jennifer A. Woyach, MD
STEERING COMMITTEE CHAIR
Professor of Medicine Division of Hematology The Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States
Chan Cheah, MBBS, DMSc
STEERING COMMITTEE MEMBER
Professor Consultant Hematologist Sir Charles Gairdner Hospital Perth, Australia
Jonathon B. Cohen, MD, MS
STEERING COMMITTEE MEMBER
Associate Professor of Hematology/Medical Oncology Co-Director of Lymphoma Program Winship Cancer Institute Emory University School of Medicine Atlanta, Georgia, United States
Barbara F. Eichhorst, MD
STEERING COMMITTEE MEMBER
Associate Professor Consultant Hematologist Department for Internal Medicine Secretary of the GLLSG University Hospital of Cologne Cologne, Germany
Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD
STEERING COMMITTEE MEMBER
Associate Professor Consultant Hematology Oxford Cancer and Haematology Centre Churchill Hospital Oxford University Hospitals NHS Foundation Trust Oxford, United Kingdom
Kami Maddocks, MD
STEERING COMMITTEE MEMBER
Professor of Clinical Internal Medicine Division of Hematology The Ohio State University Columbus, Ohio, United States
Michael Wang, MD
STEERING COMMITTEE MEMBER
Puddin Clark Endowed Professor Department of Lymphoma and Myeloma MD Anderson Cancer Center Houston, Texas, United States
Stephan Stilgenbauer, MD
STEERING COMMITTEE MEMBER
Professor Medical Director, Comprehensive Cancer Center Ulm (CCCU) Head, Early Clinical Trials Unit (ECTU) Head, Division of CLL Dept. of Internal Medicine III Comprehensive Cancer Center Ulm (CCCU) Ulm, Germany
